Most importantly, our primary purpose was to determine an optimal cut-off value for FLT3-ITD AR in a large-scale study of 1857 pediatric AML patients from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database in order to provide evidence for risk-stratified therapy and prognostic evaluation in the FLT3/ITD-positive pediatric patient population. Here, FLT3 is linked to acute myeloid leukemia.